Wikisage, the free encyclopedia of the second generation, is digital heritage
Eslicarbazepine: Difference between revisions
Jump to navigation
Jump to search
(→ATC code N03: Wikidata-logo-en.svg.png) |
m (todo rufinamide) |
||
| Line 16: | Line 16: | ||
*clobazam | *clobazam | ||
*eslicarbazepine | *eslicarbazepine | ||
*rufinamide | *[[rufinamide]] | ||
*felbamate | *felbamate | ||
*lamotrigine | *lamotrigine | ||
Revision as of 22:54, 27 January 2016
S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]
Pharmacy and chemistry
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]
Pharmacology
- Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
- Clinical utility of eslicarbazepine: current evidence
Mild inducers
After de Leon the following AED groups as mild inducers:
- clobazam
- eslicarbazepine
- rufinamide
- felbamate
- lamotrigine
- oxcarbazepine
- topiramate
- vigabatrin
- VPA
Cutaneous adverse effects
Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine
ATC code N03
Bioquivalence
References
- ↑ Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases
- ↑ Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
- ↑ A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures
- ↑ https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT
- ↑ The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AF04